Extended Data Fig. 7: Sensitivity of the SARS-CoV-2 variants D614G, Alpha, Beta and Delta to sera from convalescent individuals and vaccinated individuals.
From: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
a, ED50 values for the neutralizing activity of sera from convalescent individuals from the Orléans cohort against the four viral variants. Samples were collected 6 months after the onset of symptoms (M6 POS). The sensitivity of the D614G and Alpha variants to sera from 25 individuals has been described previously11. Fifty-six sera (including the 25 previous sera) were tested against the Beta and Delta variants. Neutralization data obtained in this study and in ref. 11 were compared (middle) and correlated (right). Similar results were obtained, allowing the datasets to be bridged. Data are mean from two independent experiments. The dotted line indicates the limit of detection (ED50 = 30). A two-sided Kruskal–Wallis test with Dunn’s multiple comparison was performed between each of the viral strains. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. D614G versus Beta, P = 0.0153; D614G versus Delta, P = 0.0008; Alpha versus Delta, P = 0.0014. b, ED50 values for the neutralizing activity of sera from individuals who received a Pfizer vaccine, sampled at week 16 (corresponding to week 13 after the second dose). Data are mean from two independent experiments. The dotted line indicates the limit of detection (ED50 = 30). A two-sided Kruskal–Wallis test with Dunn’s multiple comparison was performed between each viral strain. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. D614G versus Beta, P < 0.0001; D614G versus Delta, P = 0.0375; Alpha versus Beta, P < 0.0001; Alpha versus Delta, P = 0.0375. c–e, Fraction of neutralizers in the cohorts of convalescent or vaccinated individuals. Individuals with an ED50 of neutralization above 30 were categorized as neutralizers and are indicated in blue. Non-neutralizers are in grey. c, Analysis of convalescent individuals from the Orléans cohort collected at month 6 (left; related to a), and unvaccinated (middle; related to Fig. 2a) or vaccinated (right, related to Fig. 2a) individuals from the Strasbourg cohort collected at month 12. d, Sera from recipients of the Pfizer vaccine were sampled at week 3 (left), week 8 (middle) (both related to Fig. 2c) and week 16 (right; related to b) after vaccination. e, Sera from recipients of the AstraZeneca vaccine were sampled at week 10 (left) and week 16 (right) after vaccination (related to Fig. 2c). The numbers indicate the percentage of neutralizers.
